Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.
Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.